# Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

> **NCT03121586** · PHASE3 · TERMINATED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 995 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Pimavanserin

## Key facts

- **NCT ID:** NCT03121586
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 995 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121586, "Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03121586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*